GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF PARAGON 28, INC. (NYSE: FNA)
Paragon 28, Inc. (NYSE: FNA) states that it “develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace.” This class action was filed against the Company and three of its Officers.
A recently filed federal securities class action complaint alleges that throughout the
Period starting on May 5, 2023 ending on August 8, 2024, Paragon 28, through certain of its officers and directors, made false and/or misleading statements and/or failed to disclose that: (1) Paragon 28’s financial statements were misstated; (2) Paragon 28 lacked adequate internal controls and at times understated the extent of the issues with its internal controls; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Shareholders who purchased Paragon 28 shares between May 5, 2023 and August 8, 2024, as well as longer term shareholders who purchased prior to May 5, 2023, are encouraged to contact Joshua H. Grabar at [email protected] or Mia R. Heller at [email protected], or call 267-507-6085.